S-1226™
Cystic Fibrosis, Bronchiectasis, Asthma Rescue Drug & other chronic obstructive lung diseases including COVID-19
In Phase II Clinical Trials
S-1229™
Surfactant Dysfunction
In Pre-Clinical Development
[/one_third]
About SolAeroMed
SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.
News and Press Releases
[display-posts category=”news” include_date=”true” posts_per_page=”3″]Events
Contact CEO Dr John Dennis to arrange a call or meeting: jdennis@solaeromed.com
SolAeroMed is seeking development partners for our platform technology respiratory products.